Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
Evidence visual
KPV evidence and risk matrix
intermediate researcher fit
Evidence
Tier C
Risk
med high
Regulatory
not approved
WADA
none
FDA
unknown
Route
topical
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
KPV is a tripeptide fragment of α-MSH (residues 11-13) with reported anti-inflammatory effects. Studies show inhibition of NF-κB signaling in cell models. Evidence is primarily in vitro and animal model; dosing varies widely. Limited direct human data. Used in dermatitis/inflammation and skin/gut inflammation research contexts.
Decision path
Where KPV fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether KPV belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Anti-inflammatory effects via inhibition of NF-κB signaling (cell models).
topical, subcutaneous
In vitro and animal models; dosing varies widely.
Preclinical anti-inflammatory effects; skin/gut inflammation research.
Cell signaling endpoints are acute; clinical translation unknown.
No data.
Limited direct human data.
Unknown.
Cost at a glance
Typical cycle cost
$31.99
Estimated monthly
$42.66
Protocol style
2-4 week burst
Short burst
Estimate confidence
High confidence
Assumes roughly 4 mg–8 mg per cycle, using 2 tracked affiliated listings.
Short anti-inflammatory runs fit the evidence better than a standard monthly cycle.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for KPV.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.